We suggest that some patients with various stages of cardiac hypertrophy, including sub-clinical stages of disease, have dependence on ErbB2 to maintain cardiac function, and loss of ErbB2 activity (which can occur as a result of cancer therapy) results in heart failure. Here, ERBB2 is linked to cancer.